Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients: A double-blind, randomised, parallel-group comparison

Clinical Drug Investigation

Volumn 12, Issue 3, 1996, Pages 119-126

  Schulte, Karl Ludwig ^a,c   Beil, Stefan ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Klinikum Schwabing   (Germany)

^c Ev Krankhs Konigin E Herzberge   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG TOLERABILITY; ENCAPSULATION; FEMALE; GALLBLADDER DISEASE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INDIGESTION; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NAUSEA; NIGHTMARE; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 0029741964     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612030-00001     Document Type: Article

References (18)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
3. Livine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 322: 512-21
4. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995; 76: 10C-17C
5. Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin. pravastatin and simvastatin. Lancet 1994; 343: 1554-5
6. Mitchel YB. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis 1992; 97: S33-S39
7. Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995; 76: 54A-56A
8. Haasis R, Berber J. Fluvastatin versus Lovastatin eine randomisierte, doppelblinde, multizentrische Parallelgruppenstudie zur Effektivität und Sicherheit einer Lipidsenkung. Herz Kreisl 1995; 27: 375-80
9. Haasis R, Berger J, Andersson F, et al. A pharmacoeconomic evaluation of fluvastastin and lovastatin in primary hypercholesterolaemia. Br J Med Econ 1996; 10: 145-57
10. Ose L, Scott R and the Simvastatin-Fluvastatin Study Group. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995; 10: 127-38
11. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther 1996; 1: 23-30
12. Deslypere JP. Simvastatin-fluvastatin comparative study [correspondence]. Clin Drug Invest 1996; 11: 362-3
13. Deslypere JP. Simvstatin-fluvastatin comparative study - continued [correspondence]. Clin Drug Invest 1996; 12: 57
14. Ose L. Simvastatin-fluvastatin comparative study - continued [correspondence]. Clin Drug Invest 1996; 11: 363-4
15. Ose L. Simvastatin-fluvastatin comparative study - continued [correspondence]. Clin Drug Invest 1996; 12: 57
16. Friedewald T, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972; 6: 499-502
17. European Atherosclerosis Society. Prevention of coronary heart disease - scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-56
18. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-68C